VIVO Stock Recent News
VIVO LATEST HEADLINES
FORT MILL, SC / ACCESSWIRE / June 20, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company announced that it has received its first purchase order from Qatar. As previously announced, an initial evaluation of the VIVO product was completed earlier this year at Hamad Medical Corporation Heart Hospital in Doha.
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The post Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement appeared first on InvestorPlace.
Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a cash deal valued at $1.53 billion. Under terms of the deal, Meridian shareholders will receive $34.00 in cash for each Meridian share they own, representing a 1.3% premium to Wednesday's closing price of $33.55.
100% technical buy signals. 8 new highs and up 15.79% in the last month.
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference.
Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $99.54 million. Revenues from the life science division grew 32% Y/Y to $70.1 million.
Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President of Investor Relations Jack Kenny - Chief Executive Officer Andy Kitzmiller - Chief Financial Officer Conference Call Participants Dustin Scaringe - William Blair Operator Greetings, and welcome to Meridian Bioscience Fiscal Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.